aminolevulinic acid has been researched along with Diarrhea in 1 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients." | 2.82 | The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain. ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Saber, F | 1 |
| Aldosari, W | 1 |
| Alselaiti, M | 1 |
| Khalfan, H | 1 |
| Kaladari, A | 1 |
| Khan, G | 1 |
| Harb, G | 1 |
| Rehani, R | 1 |
| Kudo, S | 1 |
| Koda, A | 1 |
| Tanaka, T | 1 |
| Nakajima, M | 1 |
| Darwish, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes[NCT02481141] | 53 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in blood glucose levels 2 hours after breakfast (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline | -0.2 |
| 5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline | -12.9 |
| 5-ALA-SFC Through Week 12 (100 mg 2x/Day) Change From Baseline | -8.5 |
| Placebo Through Week 2 Change From Baseline | -26.5 |
| Placebo Through Week 4 Change From Baseline | -18.8 |
| Placebo Through Week 12 Change From Baseline | -33.0 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | kg (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -0.1 |
| 5-ALA-SFC Through Week 12 Change From Baseline | -0.2 |
| Placebo Through Week 6 Change From Baseline | -0.3 |
| Placebo Through Week 12 Change From Baseline | -0.8 |
The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline | 2.3 |
| 5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline | -0.2 |
| 5-ALA-SFC Through Wk 12 (100 mg 2x/Day) Change From Baseline | -3.0 |
| Placebo Through Week 2 Change From Baseline | -7.3 |
| Placebo Through Week 4 Change From Baseline | -0.8 |
| Placebo Through Week 12 Change From Baseline | -4.2 |
Change from baseline in HbA1c % (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12
| Intervention | percentage of HbA1c (Mean) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline | -0.2 |
| 5-ALA-SFC Through 4 (75 mg 2x/Day) Change From Baseline | -0.3 |
| 5-ALA-SFC Through 12 (100 mg 2x/Day) Change From Baseline | -0.7 |
| Placebo Through Week 2 Change From Baseline | -0.5 |
| Placebo Through Week 4 Change From Baseline | -0.5 |
| Placebo Through Week 12 Change From Baseline | -0.5 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -0.8 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 0.5 |
| Placebo Through Week 6 Change From Baseline | -1.6 |
| Placebo Through Week 12 Change From Baseline | -1.1 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -5.2 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 6.8 |
| Placebo Through Week 6 Change From Baseline | -7.6 |
| Placebo Through Week 12 Change From Baseline | -0.1 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -1.3 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 3.2 |
| Placebo Through Week 6 Change From Baseline | 4.5 |
| Placebo Through Week 12 Change From Baseline | 11.9 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -2.9 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 7.6 |
| Placebo Through Week 6 Change From Baseline | -11.8 |
| Placebo Through Week 12 Change From Baseline | -4.0 |
The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Week 2, Week 4, Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) | 6 |
| 5-ALA-SFC Through Week 4 (75 mg 2x/Day) | 8 |
| 5-ALA-SFC Through Week 12 (100 mg 2x/Day) | 2 |
| Placebo Through Week 2 | 3 |
| Placebo Through Week 4 | 1 |
| Placebo Through Week 12 | 1 |
1 trial available for aminolevulinic acid and Diarrhea
| Article | Year |
|---|---|
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain.
Topics: Abdominal Pain; Aminolevulinic Acid; Bahrain; Blood Glucose; Citric Acid; Cough; Diabetes Mellitus, | 2016 |